PCTs back down in Lucentis row Four PCTs have scrapped a policy of using a cheaper cancer drug in place of a licensed wet age-related macular degeneration (AMD) treatment after a legal challenge from a pharmaceutical company. by Stephen Robinson Sign in to continue Sign In Email address Password Stay signed in Trouble signing in? Reset password: Click here Need help? Email us Register FREE Limited free articles a month Free email bulletins Register Now Register Now Take a 30-day trial Join MIMS now and pay nothing for the first 30 days Join GPOnline now and pay nothing for the first 30 days Sign Up Sign Up
